Pre-clinical results of a Phase II study have proven that oncology drug candidate ENMD-2076 has significant cytotoxicity against multiple myeloma.

The trials carried out by manufacturer EntreMed showed that the angiogenic kinase inhibitor targeted multiple myeloma cells through several mechanisms that are vital for their growth and survival.

ENMD-2076 also demonstrated minimal toxicity towards haematopoietic progenitor cells, essential for the production of normal blood cells.

The orally-active inhibitor has been analysed for the treatment of cancer in multiple Phase I studies in solid tumours, multiple myeloma and leukemia.

The company is currently conducting a multi-centre Phase II study in ovarian cancer patients.